血小板生成素的研究新进展

陈陆昕; 谷冬梅; 罗微

doi:10.16766/j.cnki.issn.1674-4152.001791

血小板生成素的研究新进展

doi: 10.16766/j.cnki.issn.1674-4152.001791

天津医科大学总医院检验科，天津 300052

基金项目:

国家自然科学基金 81701968

天津市教委科研计划项目 2018KJ059

天津医科大学总医院青年孵育基金 ZYYFY2016024

详细信息

通讯作者:
罗微，E-mail：weiluo1028@sina.com

中图分类号: R973 R969
计量
- 文章访问数: 410
- HTML全文浏览量: 33
- PDF下载量: 16
- 被引次数: 0
出版历程
- 收稿日期: 2020-05-06
- 网络出版日期: 2022-02-19

Advances in the research of thrombopoietin

Department of Clinical Laboratory, General Hospital of Tianjin Medical University, Tianjin 300052, China

摘要

摘要: 血小板生成素(thrombopoietin，TPO)是血小板产生过程中关键性的调节因子，又称巨核细胞生长衍生因子。TPO可与巨核细胞上的表面受体c-Mpl结合，然后再通过多种信号通路来活化巨核细胞，促使巨核细胞发生增殖和分化从而产生血小板，继而达到提高循环中血小板水平的目的。目前，国内外已经对TPO进行了分离和克隆，并对它的蛋白结构、表达调控、生物学活性及其在临床疾病中的治疗效果进行了大量研究。这些研究揭示了TPO的新来源及其与红细胞生成素(erythropoietin，EPO)结构的异同点、TPO在体内浓度的维持机制、各代TPO药物的优缺点；同时也报道了TPO不仅在常见的血小板减少性疾病中具有良好治疗效果，对除外血液系统的其他器官或细胞也有积极的保护作用，如再生障碍性贫血、骨髓增生异常综合征、肝硬化等疾病。这一系列的研究进展发对于TPO的临床应用具有重要的指导意义，本文就上述最新进展作一综述。
- 血小板生成素 /
- 表达调控 /
- 药物研发 /
- 临床应用 /
- 研究进展
Abstract: Thrombopoietin (TPO) is a key regulator in platelet production, and also known as a megakaryocyte growth-derived factor. TPO can bind to c-Mpl, a surface receptor on megakaryocytes, activate megakaryocytes through a variety of signaling pathways to promote the proliferation and differentiation of megakaryocytes to produce platelets, and then achieve the purpose of increasing platelet levels in circulation. Now, TPO has been isolated and cloned at home and abroad, a lot of research has been done on its protein structure, expression regulation, biological activity and its therapeutic effect in clinical diseases. These studies revealed new sources of TPO and their similarities and differences with erythropoietin (EPO) structure, the maintenance mechanism of TPO concentration in vivo, and the advantages and disadvantages of TPO drugs of different generations. At the same time, TPO was reported not only in common platelets reducing diseases have a good therapeutic effect, and also have positive protective effects on the other organs or cells except the blood system, such as aplastic anemia, myelodysplastic syndrome, liver cirrhosis and so on. This series of research developments has an important guiding significance for the clinical application of TPO. This article reviews the latest developments mentioned above.
- Thrombopoietin /
- Expression regulation /
- Drug development /
- Clinical application /
- Research progress

HTML全文

参考文献(35)

[1]	GEDDIS A E, LINDEN H M, KAUSHANSKY K. Thrombopoietin: a pan-hematopoietic cytokine[J]. Cytokine Growth Factor Rev, 2002, 13(1): 61-73. doi: 10.1016/S1359-6101(01)00030-2
[2]	GROZOVSKY R, GIANNINI S, FALET H, et al. Novel mechanisms of platelet clearance and thrombopoietin regulation[J]. Curr Opin Hematol, 2015, 22(5): 445-451. doi: 10.1097/MOH.0000000000000170
[3]	CHO J, KIM H, SONG J, et al. Platelet storage induces accelerated desialylation of platelets and increases hepatic thrombopoietin production[J]. J Transl Med, 2018, 16(1): 199. doi: 10.1186/s12967-018-1576-6
[4]	KATO T, MATSUMOTO A, OGAMI K, et al. Native thrombopoietin: structure and function[J]. Stem Cells, 1998, 16(5): 322-328. doi: 10.1002/stem.160322
[5]	MUTO T, FEESE M D, SHIMADA Y, et al. Functional analysis of the C-terminal region of recombinant human thrombopoietin. C-terminal region of thrombopoietin is a "shuttle" peptide to help secretion[J]. J Biol Chem, 2000, 275(16): 12090-12094. doi: 10.1074/jbc.275.16.12090
[6]	HITCHCOCK I S, KAUSHANSKY K. Thrombopoietin from beginning to end[J]. Br J Haematol, 2014, 165(2): 259-268. doi: 10.1111/bjh.12772
[7]	KUTER D J. Milestones in understanding platelet production: a historical overview[J]. Br J Haematol, 2014, 165(2): 248-258. doi: 10.1111/bjh.12781
[8]	KAUSHANSKY K. Thrombopoiesis[J]. Semin Hematol, 2015, 52(1): 4-11. doi: 10.1053/j.seminhematol.2014.10.003
[9]	GHILARDI N, WIESTNER A, SKODA R C. Thrombopoietin production is inhibited by a translational mechanism[J]. Blood, 1998, 92(11): 4023-4030. doi: 10.1182/blood.V92.11.4023
[10]	KATO T, ODA A, INAGAKI Y, et al. Thrombin cleaves recombinant human thrombopoietin: one of the proteolytic events that generates truncated forms of thrombopoietin[J]. Proc Natl Acad Sci U S A, 1997, 94(9): 4669-4674. doi: 10.1073/pnas.94.9.4669
[11]	GROZOVSKY R, BEGONJA A J, LIU K, et al. The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling[J]. Nat Med, 2015, 21(1): 47-54. doi: 10.1038/nm.3770
[12]	PECCI A, RAGAB I, BOZZI V, et al. Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim[J]. EMBO Mol Med, 2018, 10(1): 63-75. doi: 10.15252/emmm.201708168
[13]	LEBOIS M, DOWLING M R, GANGATIRKAR P, et al. Regulation of platelet lifespan in the presence and absence of thrombopoietin signaling[J]. J Thromb Haemost, 2016, 14(9): 1882-1887. doi: 10.1111/jth.13397
[14]	ZHANG J, LIANG Y, AI Y, et al. Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review[J]. Expert Opin Pharmacother, 2017, 18(15): 1543-1551. doi: 10.1080/14656566.2017.1373091
[15]	MAKAR R S, ZHUKOV O S, SAHUD M A, et al. Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists[J]. Am J Hematol, 2013, 88(12): 1041-1044. doi: 10.1002/ajh.23562
[16]	AI-SAMKARI H, MARSHALL A L, GOODARZI K, et al. The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors[J]. Haematologica, 2018, 103(4): 169-172. doi: 10.3324/haematol.2017.180166
[17]	CANTONI S, CARPENEDO M, MAZZUCCONI M G, et al. Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers[J]. Am J Hematol, 2018, 93(1): 58-64. doi: 10.1002/ajh.24935
[18]	THACHIL J, BAGOT C, BRADBURY C, et al. A United Kingdom Immune Thrombocytopenia (ITP) Forum review of practice: thrombopoietin receptor agonists[J]. Br J Haematol, 2018, 180(4): 591-594. doi: 10.1111/bjh.14395
[19]	NEUNERT C, DESPOTOVIC J, HALEY K, et al. Thrombopoietin receptor agonist use in children: data from the pediatric ITP consortium of north America ICON2 study[J]. Pediatr Blood Cancer, 2016, 63(8): 1407-1413. doi: 10.1002/pbc.26003
[20]	BUSSEL J B, LAKKARAJA M. Thrombopoietic agents: there is still much to learn[J]. Presse Med, 2014, 43(4Pt2): e69-78. http://www.em-consulte.com/showarticlefile/883935/main.pdf
[21]	OLNES M J, SCHEINBERG P, CALVO K R, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia[J]. N Engl J Med, 2012, 367(1): 11-19. doi: 10.1056/NEJMoa1200931
[22]	DESMOND R, TOWNSLEY D M, DUMITRIU B, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug[J]. Blood, 2014, 123(12): 1818-1825. doi: 10.1182/blood-2013-10-534743
[23]	GILL H, LEUNG G M, LOPES D, et al. The thrombopoietin mimetics eltrombopag and romiplostim in the treatment of refractory aplastic anaemia[J]. Br J Haematol, 2017, 176(6): 991-994. doi: 10.1111/bjh.14024
[24]	WANG H, DONG Q, FU R, et al. Recombinant human thrombopoietin treatment promotes hematopoiesis recovery in patients with severe aplastic anemia receiving immunosuppressive therapy[J]. Biomed Res Int, 2015, 2015: 597293. doi: 10.1007/s40265-015-0363-4
[25]	BART-SMITH E E, KORDASTI S, KULASEKARARAJ A G, et al. Successful treatment of aplastic anaemia associated with HIV infection with eltrombopag: implications for a possible immunomodulatory role[J]. AIDS, 2014, 28(18): 2786-2788. doi: 10.1097/QAD.0000000000000504
[26]	TOWNSLEY D M, DESMOND R, DUNBAR C E, et al. Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes[J]. Int J Hematol, 2013, 98(1): 48-55. doi: 10.1007/s12185-013-1352-6
[27]	张凤奎, 杜俊. 血小板生成素受体激动剂改善重型再生障碍性贫血疗效的研究进展[J]. 中华血液学杂志, 2017, 38(9): 813-816.
[28]	KANTARJIAN H, FENAUX P, SEKERES M A, et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia[J]. J Clin Oncol, 2010, 28(3): 437-444. doi: 10.1200/JCO.2009.24.7999
[29]	SVENSSON T, CHOWDHURY O, GARELIUS H, et al. A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine[J]. Eur J Haematol, 2014, 93(5): 439-445. doi: 10.1111/ejh.12383
[30]	MERLI P, STROCCHIO L, VINTI L, et al. Eltrombopag for treatment of thrombocytopenia-associated disorders. Expert Opin Pharmacother[J], 2015, 16(14): 2243-2256. doi: 10.1517/14656566.2015.1085512
[31]	AFDHAL N H, GIANNINI E G, TAYYAB G, et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia[J]. N Engl J Med, 2012, 367(8): 716-724. doi: 10.1056/NEJMoa1110709
[32]	CHAN S, CHAN G C, YE J, et al. Thrombopoietin protects cardiomyocytes from iron-overload induced oxidative stress and mitochondrial injury[J]. Cell Physiol Biochem, 2015, 36(5): 2063-2071. doi: 10.1159/000430173
[33]	WU W, ZHONG W, LANG B, et al. Thrombopoietin could protect cerebral tissue against ischemia-reperfusion injury by suppressing NF-kappaB and MMP-9 expression in rats[J]. Int J Med Sci, 2018, 15(12): 1341-1348. doi: 10.7150/ijms.27543
[34]	LUM S H, GRAINGER J D. Eltrombopag for the treatment of aplastic anemia: current perspectives[J]. Drug Des Devel Ther, 2016, 10: 2833-2843. doi: 10.2147/DDDT.S95715
[35]	徐倩, 周敏. 血小板生成素受体激动剂儿童用药的研究进展[J]. 中国小儿血液与肿瘤杂志, 2018, 23(5): 229-231. doi: 10.3969/j.issn.1673-5323.2018.05.002